Texas Children's Cancer and Hematology Center Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children


This is a clinical trial to compare a medication called eltrombopag to standard treatments (steroids, IVIG, or anti-D globulin) for children with newly diagnosed ITP. Eltrombopag is a medication that tells the bone marrow to make more platelets and, when tolerated and effective, can be continued until the ITP resolves or therapy is no longer needed. Eltrombopag is approved for children with chronic ITP so its safety in children has already been shown.

Eligibility Criteria

  • Ages eligible for study: 1-18 years
  • Platelets <30 x 10^9/L at screening
  • Requires pharmacologic treatment from the perspective of the treating clinician
  • Newly Diagnosed ITP (<3 months from diagnosis)

Detailed inclusion and exclusion criteria at clinicaltrials.gov.


Amanda B. Grimes, MD
Texas Children’s Hematology Center


Bogdan Dinu
Texas Children’s Hematology Center